Combination Tx with DC/AML fusion veTcs and SAR eradicates AML engraftment in a xenograft murine model. (A) NSG mice were inoculated with patient-derived AML cells (n = 25). After detection of human engraftment, the animals were treated on day 36 after inoculation with either veTcs or SAR or combination of both (n = 5 per cohort). Organ assessment for AML burden was performed 45 days after starting Tx (81 days after inoculation). (A) Bone marrow samples were analyzed by flow cytometry for hCD45⁺CD123⁺ AML cells. (B) Representative flow plot of single mouse bone marrow from each cohort. (C) hCD45⁺CD38⁺ values from bone marrow combined for experiments in panel A and Figure 3B. No Tx (n = 9), uTcs + IgG (n = 10), uTcs + SAR (n = 10), veTcs + IgG (n = 10), veTcs + SAR (n = 10). Mean with SEM is shown in panels A,C. Statistical analysis was performed using GraphPad Prism 10.0 (GraphPad Software Inc). Pairwise comparison was performed using Kruskal-Wallis test, with Dunn multiple comparisons and Benjamini-Hochberg FDR correction. ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001; ∗∗∗∗P ≤ .0001. (D) Number of animals with the indicated percentage of hCD123⁺ cells in the bone marrow as depicted in panel A, Fisher exact test.